Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 8
Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus
Authors Hagihara M, Umemura, Mori, Mikamo
Received 10 December 2011
Accepted for publication 17 January 2012
Published 17 February 2012 Volume 2012:8 Pages 79—86
DOI https://doi.org/10.2147/TCRM.S23875
Review by Single anonymous peer review
Peer reviewer comments 3
Mao Hagihara1, Takumi Umemura1, Takeshi Mori1,2, Hiroshige Mikamo1
1Department of Infection Control and Prevention, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan; 2Division of Pharmaceutical Science, Faculty of Pharmacy, Meijo University, Nagoya, Aichi, Japan
Abstract: Daptomycin is a lipoglycopeptide antibacterial drug that is rapidly bactericidal for methicillin-resistant Staphylococcus aureus (MRSA) infection and has antibiotic activity against a wide range of Gram-positive organisms. It has been approved by the Ministry of Health, Labor and Welfare in Japan for the treatment for bacteremia, right-sided endocarditis, and skin and skin-structure infections, such as necrotizing fasciitis, due to MRSA on the basis of a Phase III trial conducted in Japan since July, 2011. In Japanese Phase I and III trials, daptomycin therapy given at 4 mg/kg and 6 mg/kg once per day was well tolerated and effective as standard therapy for the treatment of acute bacterial skin and skin-structure infections and bacteremia caused by MRSA, but side effects remain to be evaluated in large-scale trials.
Keywords: daptomycin, methicillin-resistant Staphylococcus aureus (MRSA), Japan
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.